pufa 22:3

PUFA 22:3, also known as docosatrienoic acid, is a very long-chain polyunsaturated fatty acid (PUFA) with 22 carbon atoms and three cis double bonds occurring at positions 13, 16, and 19 along the hydrocarbon chain. It is structurally categorized within the omega-3 (n-3) family of fatty acids, which are characterized by the location of the first double bond three carbons from the methyl end of the molecule. Docosatrienoic acid (22:3n-3) differs from more commonly discussed omega-3 fatty acids, such as EPA (20:5n-3) and DHA (22:6n-3), in the number and placement of double bonds, making it rarer in human tissues and dietary sources. Scientific descriptions of docosatrienoic acid note that it is not typically detected in large quantities in normal phospholipid PUFA pools but can be synthesized via elongation and desaturation pathways from shorter omega-3 precursors such as ALA (alpha-linolenic acid). The molecular formula for docosatrienoic acid is C22H38O2, and its rare presence in biochemical studies has drawn research interest regarding potential unique roles in lipid metabolism and signaling pathways. Unlike essential fatty acids such as ALA and linoleic acid, which must be obtained from the diet because humans lack the enzymes to introduce cis double bonds beyond the ninth carbon, PUFA 22:3 is part of the extended metabolic network of PUFAs and can be produced endogenously from precursor fatty acids. The broader family of polyunsaturated fatty acids plays essential roles in human nutrition and physiology. PUFAs encompass both omega-3 and omega-6 fatty acids and are distinguished by having two or more double bonds in their carbon chains. They are integral components of cell membranes, contributing to membrane fluidity and structure. They also serve as precursors for bioactive lipid mediators, including eicosanoids and resolvins, which regulate inflammation and immune responses. Most dietary guidance and research focus on more abundant PUFAs, such as ALA, EPA, DHA, and linoleic acid, due to their established roles in health and disease prevention. However, rare PUFAs like docosatrienoic acid have been identified and are being explored for potential anti-inflammatory and biochemical signaling properties. Some biochemical studies report that docosatrienoic acid can modulate enzymatic kinetics in model systems, though human clinical data remain very limited. In summary, PUFA 22:3 is a specific molecular form within the broader class of omega-3 PUFAs, with limited direct dietary data but relevance within the metabolic network of polyunsaturated fats that influence cellular function and physiology.

Polyunsaturated fatty acids (PUFAs) in general are essential to human physiology. They contribute to the structural integrity and fluidity of cell membranes and serve as precursors for a wide range of bioactive lipid mediators that regulate inflammation, immune response, and vascular function. Although PUFA 22:3 itself is rare and not widely quantified in typical diets or human tissues, it belongs to the omega-3 family of fatty acids, which includes well-studied members such as alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). EPA and DHA are commonly associated with cardioprotective, anti-inflammatory, and neuroprotective effects. Research indicates that omega-3 fatty acids, when consumed in adequate amounts, are incorporated into cell membranes, altering membrane composition and affecting the synthesis of eicosanoids and other lipid mediators involved in inflammation. These mediators include prostaglandins, thromboxanes, and resolvins, which help modulate inflammatory pathways and contribute to cardiovascular and immune health. For example, clinical trials have suggested that supplementation with EPA and DHA can reduce triglyceride levels by approximately 15% in adults with elevated levels, a factor relevant to cardiovascular disease risk management. The mechanisms by which omega-3 PUFAs exert their effects involve alterations in gene expression, modulation of signal transduction cascades, and influences on membrane protein function. Although studies specifically quantifying docosatrienoic acid (PUFA 22:3) in human clinical outcomes are scarce, scientific interest in very long-chain PUFAs (VLC-PUFAs) recognizes that structural variants within this class may have distinct roles in cellular signaling. In laboratory models, docosatrienoic acid has been observed to interact with lipid metabolic enzymes and may influence neutrophil receptor binding and DNA polymerase activity at certain concentrations. These biochemical interactions suggest potential involvement in inflammatory regulation and cellular proliferation pathways, although direct evidence in human health outcomes is currently limited. In the broader context of omega-3 fatty acids, substantial epidemiologic and clinical evidence supports roles in reducing cardiovascular disease risk, modulating blood pressure, and supporting neurodevelopment and cognitive function. Regular consumption of foods rich in EPA and DHA has been linked to lower incidence of coronary heart disease, improved endothelial function, and beneficial effects on lipid profiles. Omega-3 PUFAs also may play a role in immune regulation and inflammatory conditions such as rheumatoid arthritis. Some reviews suggest that incorporating omega-3 rich foods or supplements into the diet can help alleviate symptoms of joint pain and stiffness in certain individuals. In addition, dietary omega-3s have been explored for potential roles in cognitive aging and mood disorders, with mixed evidence. The anti-inflammatory effects and impacts on cell signaling pathways provide plausible mechanisms through which broad classes of PUFAs, including rare forms like PUFA 22:3, could contribute to health, but more targeted research is needed to understand the unique functions of docosatrienoic acid itself.

There is no established dietary reference intake, recommended daily allowance (RDA), or tolerable upper intake level (UL) specifically for docosatrienoic acid (PUFA 22:3). Instead, dietary guidance for fatty acids focuses on broader categories, particularly omega-3 polyunsaturated fatty acids and their essential precursors. The National Institutes of Health Office of Dietary Supplements (NIH ODS) provides comprehensive fact sheets on omega-3 fatty acids, which include alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). These guidance materials emphasize that the human body cannot synthesize essential PUFAs like ALA and linoleic acid de novo, and they must be obtained through the diet. While docosatrienoic acid may be produced endogenously via elongation and desaturation pathways from shorter chain omega-3 fatty acids like ALA, it does not have its own intake recommendations because its dietary levels and biological impacts are not well characterized. For broader context, Adequate Intakes for total ALA have been established: approximately 1.6 grams per day for adult males and 1.1 grams per day for adult females. These values reflect general guidance for meeting essential omega-3 fatty acid needs through diet. Intake of longer chain omega-3s, such as EPA and DHA, is often recommended at around 250–500 milligrams per day combined for cardiovascular and overall health benefits, although these are not formal RDAs but rather consensus dietary targets used by many health organizations. Dietary guidelines generally encourage consumption of fatty fish, seeds, and nuts as part of a balanced diet to achieve beneficial levels of omega-3 fatty acids. Because docosatrienoic acid is considered a very long-chain derivative and is present in minimal amounts in typical foods, focusing on achieving adequate intake of its metabolic precursors and more abundant omega-3 fatty acids (ALA, EPA, DHA) helps ensure that overall PUFA metabolism is supported. Factors that influence individual needs for PUFAs include age, sex, physiological status such as pregnancy or lactation, underlying health conditions, and dietary patterns. Individuals with increased inflammatory conditions, cardiovascular risk factors, or specific metabolic disorders may benefit from tailored dietary approaches to ensure sufficient intake of omega-3 fatty acids, often under the guidance of a healthcare professional. In summary, because there is no specific RDA for PUFA 22:3, general recommendations for omega-3 fatty acid intake serve as practical targets to support PUFA metabolism and broader health outcomes.

Because PUFA 22:3 (docosatrienoic acid) is a rare and poorly quantified fatty acid, deficiency of this specific molecule has not been systematically defined in clinical nutritional science. However, deficiency of the broader class of polyunsaturated fatty acids, particularly the essential omega-3 and omega-6 fatty acids from which docosatrienoic acid is metabolically derived, can manifest in specific signs and symptoms. Essential fatty acids like alpha-linolenic acid (ALA, an omega-3 fatty acid) and linoleic acid (LA, an omega-6 fatty acid) cannot be synthesized by humans and must be obtained from the diet. When diets are severely low in these essential fatty acids, clinical signs of deficiency may emerge. Traditional essential fatty acid deficiency is characterized by a distinct set of symptoms including scaly dermatitis, increased susceptibility to infection, poor wound healing, and alopecia. Laboratory markers of EFA deficiency include lowered levels of essential fatty acids and their metabolites in plasma phospholipids, and elevated levels of Mead acid, an indicator of severe essential fatty acid deficiency. Individuals at risk for essential fatty acid deficiency include those on extremely restricted diets lacking in plant or marine sources of PUFAs, individuals with malabsorption syndromes such as cystic fibrosis or short bowel syndrome, and those receiving long-term parenteral nutrition without adequate lipid supplementation. In these contexts, clinical signs of EFA deficiency may include dry, flaky skin, brittle hair, and impaired growth in children. Systemic effects can involve dysregulation of inflammatory responses, impaired immune function, and altered lipid metabolism. Because docosatrienoic acid is a downstream product within the omega-3 metabolic pathway, its levels may decline in the context of overall omega-3 insufficiency, although direct clinical measurements and reference ranges for PUFA 22:3 are not established. Functional consequences of insufficient omega-3 PUFA intake can include suboptimal cardiovascular and cognitive health outcomes. Low intake of EPA and DHA has been associated with higher triglyceride levels, poorer endothelial function, and increased markers of inflammation. This pattern underscores the importance of consuming a balanced variety of PUFAs to support overall lipid homeostasis and prevent broader deficiency effects. In practice, health professionals assess fatty acid status primarily through measurement of plasma or erythrocyte levels of key PUFAs such as ALA, EPA, and DHA rather than rare fatty acids like docosatrienoic acid. Thus, while there are no specific deficiency diseases attributed to PUFA 22:3 itself, ensuring adequate intake of its metabolic precursors and related omega-3 fatty acids helps prevent functional deficits associated with polyunsaturated fatty acid inadequacy.

Direct dietary sources of docosatrienoic acid (PUFA 22:3) are not well characterized because this fatty acid occurs in very low concentrations in most foods and is seldom quantified separately in food composition databases. Therefore, identifying foods rich in PUFA 22:3 specifically is challenging. However, foods that are high in omega-3 polyunsaturated fatty acids (PUFAs), particularly those that supply abundant ALA, EPA, and DHA, support overall PUFA metabolism and may provide substrate for endogenous metabolic pathways that yield longer chain derivatives including docosatrienoic acid. Common food sources rich in omega-3 PUFAs include oily fish, seeds, nuts, and certain plant oils. These foods are well documented to deliver significant amounts of EPA and DHA (marine sources) or ALA (plant sources). Oily fish such as salmon, mackerel, sardines, anchovies, and herring are among the richest dietary sources of long-chain omega-3 PUFAs. Typical 3-ounce (85 g) servings of cooked salmon provide approximately 1.1–1.9 grams of combined EPA and DHA, while sardines and herring deliver similar quantities. These marine fatty acids are directly incorporated into cell membranes and can be metabolized into longer chain derivatives through enzymatic elongation and desaturation, although the specific conversion to PUFA 22:3 in humans remains poorly quantified. Plant seeds such as flaxseed and chia seeds are excellent sources of ALA, a precursor of longer chain omega-3 fatty acids. Flaxseed oil and chia seeds may supply several grams of ALA per serving, making them valuable for individuals seeking to boost total omega-3 PUFA intake. Walnuts are another convenient plant source, providing omega-3s along with fiber and antioxidants. Other sources of omega-3 PUFAs include soybeans, hemp seeds, and certain vegetable oils like canola oil. While the conversion of ALA to longer chain PUFAs in humans is limited and inefficient, these plant-based sources nonetheless contribute to the overall pool of omega-3 fatty acids. Microalgae and algae-derived oils are increasingly used to deliver EPA and DHA, especially in vegetarian and vegan diets. Given the rarity of docosatrienoic acid itself in typical dietary patterns, focusing on diverse sources of omega-3 PUFAs supports overall lipid nutrition and may facilitate endogenous synthesis of various PUFA metabolites. The following list provides representative foods that are high in PUFA content (with emphasis on omega-3s), serving as proxies for foods that could indirectly support levels of PUFA 22:3 through metabolic pathways: - Salmon (Atlantic, cooked, 3 oz): ~1.5 g EPA+DHA - Sardines (canned in oil, 3 oz): ~1.0 g EPA+DHA - Mackerel (Atlantic, cooked, 3 oz): ~1.7 g EPA+DHA - Herring (Atlantic, cooked, 3 oz): ~1.1 g EPA+DHA - Anchovies (canned, 3 oz): ~0.9 g EPA+DHA - Flaxseeds (1 tbsp ground): ~2.4 g ALA - Chia seeds (1 oz): ~5 g ALA - Walnuts (1 oz): ~2.6 g ALA - Soybeans (cooked, 1 cup): ~0.4 g ALA - Hemp seeds (3 tbsp): ~2.5 g ALA - Canola oil (1 tbsp): ~1.3 g ALA - Sardine oil (1 tbsp): high EPA+DHA - Trout (rainbow, cooked, 3 oz): ~0.9 g EPA+DHA - Oysters (3 oz): ~0.5 g EPA+DHA - Algal oil supplements: variable EPA+DHA While these foods do not list docosatrienoic acid explicitly, consuming a mixture of these high-omega-3 sources ensures a robust intake of PUFAs that support lipid metabolism, potentially including minor components like PUFA 22:3.

Polyunsaturated fatty acids (PUFAs), including omega-3 varieties, are absorbed in the small intestine after dietary ingestion. In the intestinal lumen, dietary triglycerides are emulsified by bile salts and pancreatic lipases, resulting in free fatty acids and monoglycerides that form micelles. These micelles facilitate passive diffusion across the brush border of enterocytes. Once inside enterocytes, long-chain fatty acids are re-esterified into triglycerides, incorporated into chylomicrons, and transported via the lymphatic system into the systemic circulation. This absorption process applies broadly to long-chain PUFAs such as EPA and DHA as well as minor constituents from dietary lipids. The relative bioavailability of specific fatty acids depends on their chain length, degree of unsaturation, and food matrix effects. For example, PUFAs in the form of triglycerides from whole foods like fish or nuts are generally well absorbed, whereas certain supplemental forms (ethyl esters) may have lower absorption unless taken with meals containing fat. The efficiency of absorption for rare fatty acids like docosatrienoic acid has not been specifically studied, but its structural similarity to other long-chain omega-3 fatty acids suggests it would follow similar uptake pathways. Factors that enhance PUFA absorption include the presence of dietary fat to stimulate bile release, adequate pancreatic enzyme activity, and sufficient micelle formation. Conversely, conditions that impair fat digestion and absorption, such as pancreatic insufficiency, cholestatic liver disease, or small bowel resection, can reduce PUFA bioavailability. Dietary fiber can also influence absorption by binding bile acids and reducing micelle stability. Bioavailability can differ between food sources; marine sources with EPA and DHA typically show high incorporation into plasma phospholipids, whereas the conversion of plant-derived ALA into longer chain PUFAs like EPA and DHA in humans is limited. This metabolic conversion involves desaturation and elongation enzymes, with low overall efficiency (often d as <15% for EPA and even lower for DHA). As docosatrienoic acid is a downstream metabolic product, its presence in tissues is influenced by both dietary intake of precursor PUFAs and individual metabolic capacity. Genetic polymorphisms in desaturase and elongase enzymes can alter PUFA metabolism, affecting tissue levels of various long-chain PUFAs. Overall, consuming PUFAs in the context of balanced meals that include other fats and nutrients supports optimal absorption and incorporation into body tissues.

There are currently no supplements marketed specifically for docosatrienoic acid (PUFA 22:3), as this fatty acid is rare and not well quantified in standard nutritional research or food composition data. Instead, most dietary supplements focus on more common omega-3 fatty acids such as EPA and DHA, delivered through fish oil, krill oil, or algal oil preparations, and on plant-derived ALA from flaxseed or chia seed oils. These supplements aim to enhance overall omega-3 PUFA status, supporting cardiovascular, cognitive, and anti-inflammatory processes. Because docosatrienoic acid is part of the broader metabolic network of omega-3 PUFAs, achieving adequate intake of EPA, DHA, and ALA may indirectly influence endogenous levels of docosatrienoic acid and other minor PUFA metabolites. Omega-3 supplements are commonly recommended for individuals who do not consume sufficient dietary sources of long-chain PUFAs, such as those with low fish intake or dietary restrictions. Evaluating whether to take omega-3 supplements involves considering individual dietary patterns, health goals, and potential benefits versus risks. Clinical evidence suggests that EPA and DHA supplementation can help lower triglyceride levels, support heart health, and modulate inflammatory responses. Some studies have also explored the role of omega-3s in joint health and mental well-being, though findings vary by condition and dosage. As with any supplement, quality matters: reputable products should be third-party tested for purity, potency, and absence of contaminants like heavy metals. Typical supplemental doses of combined EPA and DHA range from 250–1000 mg/day for general health, with higher therapeutic doses used under medical supervision for specific conditions such as hypertriglyceridemia. Because no specific PUFA 22:3 supplement exists, focusing on established omega-3 forms helps ensure broader health benefits. Healthcare professionals may recommend omega-3 supplementation for individuals with low dietary intake of fish or omega-3 rich plant foods, those with elevated cardiovascular risk factors, or certain pregnancy contexts where DHA is important for fetal development. It’s important to discuss supplementation with a healthcare provider, especially for individuals on anticoagulant medications, those with bleeding disorders, or people with complex medical conditions. Ultimately, supplements are one tool to support PUFA intake, whereas a balanced diet rich in natural food sources remains the foundation for optimal nutrition.

There are no established toxicity thresholds or tolerable upper intake levels (ULs) specifically for docosatrienoic acid (PUFA 22:3) due to its rarity and lack of targeted clinical research. Nutritional guidance for fatty acids tends to focus on more common forms such as EPA and DHA. For combined EPA and DHA intake from supplements, regulatory authorities such as the U.S. Food and Drug Administration (FDA) generally consider intakes up to about 5 grams per day to be safe for most adults, although higher doses have been used therapeutically under medical supervision. At these levels, side effects from omega-3 supplements are usually mild and may include gastrointestinal symptoms such as fishy aftertaste, nausea, and diarrhea. Because PUFA 22:3 is structurally similar to common long-chain omega-3 PUFAs, excessive intake from highly concentrated sources could theoretically contribute to similar side effects, although direct evidence is lacking. Excessive intake of omega-3 supplements can also influence bleeding risk, particularly in individuals taking anticoagulant medications. High doses of omega-3 fatty acids may impair platelet aggregation and prolong bleeding time, which could be clinically relevant in people with bleeding disorders or those undergoing surgery. It’s important that individuals considering high-dose omega-3 supplementation discuss it with their healthcare provider to balance potential benefits and risks. Because docosatrienoic acid itself is not available as a standalone supplement and is present in negligible amounts in foods, concerns about toxicity are primarily relevant for overall omega-3 PUFA intake rather than this specific molecule. As with all nutrients, moderation and adherence to general dietary guidance help prevent adverse effects. Ensuring a varied diet with appropriate PUFA sources, while avoiding excessive supplementation beyond recommended levels without medical advice, supports safe and balanced nutrition.

Docosatrienoic acid (PUFA 22:3) itself has not been studied for specific drug interactions due to its rarity and the lack of standalone supplements. However, broader classes of polyunsaturated fatty acids, particularly omega-3 fatty acids like EPA and DHA, are known to interact with certain medications, and these interactions are relevant when considering overall PUFA intake. One well-documented interaction involves omega-3 supplements and anticoagulant or antiplatelet medications. High doses of omega-3 fatty acids may enhance the effects of drugs such as warfarin (Coumadin), aspirin, and other antiplatelet agents, potentially increasing bleeding risk. This occurs because omega-3 PUFAs can influence platelet aggregation and clotting pathways. Individuals taking these medications should consult healthcare providers before initiating high-dose omega-3 supplementation to ensure safe management of bleeding risk. Additionally, omega-3 supplements may interact with blood pressure medications. While generally beneficial for cardiovascular health, combining omega-3 PUFAs with antihypertensive drugs could theoretically augment blood pressure-lowering effects, necessitating monitoring to avoid hypotension. Another area of consideration involves lipid-lowering drugs such as statins. Omega-3 supplements are often used to help reduce elevated triglyceride levels, and some studies suggest additive effects when used alongside statins. However, patients should always coordinate such combined therapy under medical supervision to monitor lipid levels and liver function markers. Because omega-3 PUFAs influence metabolic pathways, potential interactions with other medications that affect lipid metabolism and inflammatory pathways may exist, though evidence is limited. Healthcare providers evaluate medication regimens in the context of overall diet and supplement use to prevent unforeseen interactions. While docosatrienoic acid itself is unlikely to be the primary driver of drug interactions due to its minimal dietary and supplemental presence, attention to the broader PUFA and omega-3 intake is essential when considering interactions with anticoagulants, antiplatelet drugs, antihypertensives, and other cardiovascular agents.

Common Forms: fish oil, krill oil, algal oil, flaxseed oil

Typical Doses: 250–1000 mg EPA+DHA/day for general health

When to Take: with meals to enhance absorption

Best Form: triglyceride or re-esterified triglyceride forms

⚠️ Interactions: warfarin/anticoagulants, antiplatelet agents, antihypertensives